The European Union has granted CE mark to NeoChord's minimally invasive device, DS1000, that allows implantation of artificial chordae tendinae for the repair of mitral valve prolapse, via a transapical, off-pump procedure.
In addition, the company has commenced 50-patient Transapical Artificial Chordae Tendinae (TACT) Registry, with first commercial European procedures scheduled for Q1 2013.
NeoChord technolgy primary inventor Giovanni Speziali said the company is pleased with the short- and medium-term clinical outcomes to date using the DS1000 technology to treat patients suffering from mitral regurgitation.
"The NeoChord procedure allows patients an alternative to still undergo a quality repair without enduring the rigors of traditional treatment via open-chest surgery performed on a stopped heart," Speziali added.
